Senior Management Team

Guo-Liang Yu, Ph.D., President, CEO and Chairman of the Board

A biotechnologist and entrepreneur with more than 12 years of experience in genomics, and 24 years of experience in life sciences research. Before co-founding Epitomics, Dr. Yu was Senior Vice-President of Research and Development at Mendel Biotechnology Inc. At Mendel Biotechnology, Dr. Yu established a robust functional genomics program, exceeded all six milestones for the Research Agreement with Monsanto and Savia, and managed over 60 Ph.D. scientists and research associates. Before joining Mendel Biotechnology, Dr. Yu was with Human Genome Sciences, Inc., a prominent genomics company, as one of the first Senior Scientists involved in the establishment of the high throughput gene discovery program. While at Human Genome Sciences, Dr. Yu led the technology development group and cancer group. He identified and characterized numerous genes for therapeutic protein and drug discovery. Dr. Yu was a Post-doctoral Fellow at the Harvard Medical School. He holds a Ph.D. degree in Molecular Biology from the University of California, Berkeley and a B.S. degree in Biochemistry from Fudan University, Shanghai, China. Dr. Yu is also the founder of the Chinese Biopharmaceutical Association headquartered in Washington DC. He is co-inventor and co-author of over 100 patents and scientific articles.

Peter Li, PhD, Senior Vice-President of Product Development

Peter Li joined Epitomics as VP of Life Sciences in December 2003. Dr. Li brought to Epitomics broad experience as a venture capitalist and a biotechnology industrial insider. As Vice President at Kenson Ventures, LLC., Dr. Li consulted for biotech startups on business strategies, operations, marketing and business development. He has served as a member of Board of Directors, an observer to the Board, or a business advisor for many biotech companies. Prior to Kenson Ventures, Dr. Li also worked in biotechnology corporate finance at investment bank RBC Capital Markets. Dr. Li was also the head of Peptide Antibody Development at Santa Cruz Biotechnology, Inc. Prior to that, Dr. Li was a postdoctoral research fellow at the Department of Molecular and Cell Biology, University of California, Berkeley. Dr. Li also earned his M.B.A. from University of California, Berkeley. He received his Ph.D. in biochemistry from Ohio State University, where he was a University Presidential Fellow, and his B.S. from University of Science and Technology of China.

Weimin Zhu, Vice President of Antibody Technology

Before co-founding Epitomics, Mr. Zhu served as a research scientist at Bayer Corporation where he developed a series of high throughput assays for anti cancer drug screen and contributed to the discovery of several drug candidates. Prior to Bayer, Mr. Zhu was a senior associate specialist at UCSF where he pioneered rabbit monoclonal antibody technology (created new rabbit fusion partner 240E-W) and established the high throughput system for rabbit hybridoma generation that has become the core technology of Epitomics, Inc. Using this technology, he led his team developing a large number of high quality rabbit MAbs and identifying a number of cancer specific molecules. He received his M.S. in Cell Biology at Xiamen University, China. Mr. Zhu was a Senior Research Fellow at the Institute of Pathology of Zhejiang Medical University where he began his monoclonal antibody study. Mr. Zhu was a visiting scientist at the Institute of Pharmacological Sciences of Milan, Italy, and subsequently at the Gladstone Cardiovascular Disease Institute at UCSF. Mr. Zhu is the author of more than 20 scientific publications and co-inventor of several patents.

Laurie Gee, Vice-President of Finance

Laurie Gee joined Epitomics in November 2006 as Vice President of Finance. Ms. Gee has over 19 years of experience in financial management in large and small companies. Prior to joining Epitomics, she was Director of Finance and Business Affairs of Metreon-A Sony Entertainment Center from 2000 to 2005, where she was instrumental in developing the company’s financial infrastructure and made numerous contributions to the company’s commercial growth. She designed and built a team for the newly built Sony facility who strived to make the company reach its’ financial growth. Ms. Gee was Vice President of Finance and Administration of Castelle Inc., from 1998 to 2000. She was also CFO and Controller for Kidsoft Inc. from 1996 to 1997. Ms. Gee was Director of Finance for Elonex Technologies from 1995 to 1996 and was Assistant Controller for The North Face Inc. from 1993 to 1995. She started her career at Arthur Andersen as a Certified Public Accountant in the Business Advisory practice from 1988 to 1992. Ms. Gee holds a B.S. degree from San Francisco State University in Accounting.